PharmaPoint: Irritable Bowel SyndromeGlobal Drug Forecast and Market Analysis to 2023
Single User License - $10995 Site User License - $21990 Corporate User License - $32985 Publication Date - Dec 2014 Pages - 257 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs. As of October 2014, there were four products indicated for IBS in the 7MM. These include the constipation-predominant IBS (IBSC) therapies, Sucampo/Takeda/Abbott’s Amitiza (lubiprostone) and Ironwood/Actavis/Almirall/Astellas’ Linzess (linaclotide), and the diarrhea-predominant IBS (IBS-D) therapies, Prometheus’ Lotronex (alosetron) and Astellas’ Irribow (ramosetron). Contact: debora@reportstack.com Reportstack Market Research
Scope Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Annualized IBS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IBS market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
Contact: debora@reportstack.com Reportstack Market Research
Key Findings The IBS market value will be driven by the increasing uptake of Ironwood/Actavis/Almirall/Astellas’ Linzess and its expected launch in all the major European markets and Japan, the anticipated label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan for IBS-D, the potential introduction of four pipeline drugs for the treatment of IBS, and the increasing prevalent cases of IBS. The main corporate strategy trend in the IBS market is for companies to enter into partnerships for the successful codevelopment and co-marketing of products in the different global regions. The most pressing unmet need in the IBS market is for the development of drugs with improved efficacy.
Contact: debora@reportstack.com Reportstack Market Research
Companies Mentioned Abbott Actavis Ajinomoto Alba Albireo Alfa Wassermann Almirall AltheRx Ardelyx Astellas AstraZeneca Bama-Geve Dong-A Socio Drais Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research